[go: up one dir, main page]

WO2019246074A1 - Tablette sublinguale d'antidépresseur et d'anxiolytique - Google Patents

Tablette sublinguale d'antidépresseur et d'anxiolytique Download PDF

Info

Publication number
WO2019246074A1
WO2019246074A1 PCT/US2019/037698 US2019037698W WO2019246074A1 WO 2019246074 A1 WO2019246074 A1 WO 2019246074A1 US 2019037698 W US2019037698 W US 2019037698W WO 2019246074 A1 WO2019246074 A1 WO 2019246074A1
Authority
WO
WIPO (PCT)
Prior art keywords
ingredient
tablet
sublingual
base
mold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/037698
Other languages
English (en)
Inventor
Anthony H. SALCE, Jr.
William F. GREENWOOD
Shivsankar MISIR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synergistic Therapeutics LLC
Original Assignee
Synergistic Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/011,085 external-priority patent/US20180296478A1/en
Application filed by Synergistic Therapeutics LLC filed Critical Synergistic Therapeutics LLC
Publication of WO2019246074A1 publication Critical patent/WO2019246074A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • Antidepressant and antianxiety treatments may include therapies that target monoaminergic (MA) systems.
  • Antidepressant and antianxiety treatments that target monoaminergic (MA) systems may require 4-6 weeks of administration to achieve effects, may include unpleasant side effects, may possess modest efficacy rates, and may display significant relapse rates.
  • N-Methyl-D-aspartate (NMDA) receptor antagonists may be used as anesthetics and hallucinogenic recreational drugs.
  • Ketamine, diethyl ether, dizocilpine, memantine, phencyclidine, nitrous oxide, and dextromethorphan may be MNDA receptor antagonists.
  • sublingual antidepressant and antianxiety tablets are described.
  • the tablets may comprise sublingual tablet base and ketamine.
  • the tablets may comprise 2.00 weight percent to 23.00 weight percent ketamine.
  • methods to produce sublingual antidepressant and antianxiety tablets may comprise placing sublingual tablet base into a chamber.
  • the methods may comprise adding a first ingredient into the chamber.
  • the first ingredient may include ketamine.
  • the methods may comprise mixing the first ingredient into the sublingual tablet base in the chamber to form a mixture.
  • the methods may comprise pressing the mixture into a mold.
  • the methods may comprise drying the mixture in the mold to form the tablet.
  • sublingual antidepressant and antianxiety tablets are described.
  • the tablets may comprise sublingual tablet base and ketamine.
  • the tablet may comprise 0.005 to 0.050 grams of ketamine.
  • Fig. 1 illustrates an example system that can be utilized to produce a sublingual antidepressant and antianxiety lozenge
  • Fig. 2 illustrates a flow diagram of an example process to produce a sublingual antidepressant and antianxiety lozenge
  • Fig. 3 illustrates an example system that can be utilized to produce a sublingual antidepressant and antianxiety tablet
  • Fig. 4 illustrates a flow diagram of an example process to produce a sublingual antidepressant and antianxiety tablet
  • Fig. 1 illustrates an example system that can be utilized to produce a sublingual antidepressant and antianxiety lozenge, arranged in accordance with at least some embodiments presented herein.
  • a sublingual antidepressant and antianxiety lozenge may be effective in the treatment of depression and anxiety.
  • System 100 may include a chamber 20, a heater 30 and a lozenge mold 90.
  • a troche base 10 may be placed in within chamber 20 and melted by heat from heater 30 to produce melted troche base 15.
  • Troche base 10 may be a blend of polyethylene glycols (PEGs).
  • Troche base 10 may be white and/or translucent in appearance and be in the shape of small pellet pieces.
  • Troche base 10 may be solid at room temperatures of 20 to 25 degrees Celsius.
  • Heater 30 may supply heat to increase a temperature of troche base 10 to about 45 to 60 degrees Celsius and melt troche base 10 to produce melted troche base 15.
  • a mixing instrument 25 may be inserted into chamber 20 and ingredients 40, 50, 60 70, and 80 may each be individually and respectively added and blended into melted troche base 15.
  • Mixing instrument 25 may be a manual mixing instrument such as a spoon or whisk, or an automated mixer.
  • Ingredient 40 may be in powder form. Ingredient 40 may include ketamine.
  • Ingredient 40 may include ketamine hydrochloride (HC1) powder.
  • Ingredient 50 may be in powder form.
  • Ingredient 50 may include silica gel powder.
  • Ingredient 50 may be granular, vitreous in appearance, and porous.
  • Ingredient 50 may be tough and hard in texture.
  • Ingredient 50 may include a strong affinity for water molecules.
  • Ingredient 50 may be silicon dioxide produced synthetically from sodium silicate.
  • Ingredient 50 may have an average pore size of about 2.4 nanometers.
  • Ingredient 50 may be a suspending agent and may keep materials from settling at the bottom of a mold cavity during cooling.
  • Ingredient 60 may be in powder form.
  • Ingredient 60 may include a weak organic tribasic acid.
  • Ingredient 60 may include citrate.
  • Ingredient 60 may include citric acid powder.
  • Ingredient 60 may include an acidifier, a flavoring, a chelating agent, or a pH adjusting agent.
  • Ingredient 60 may include a processing aid.
  • Ingredient 70 may be in powder form.
  • Ingredient 70 may include acacia powder.
  • Ingredient 70 may include gum exuded from the acacia tree.
  • Ingredient 70 may include dietary fiber that can dissolve in water.
  • Ingredient 70 may add texture and smoothness to a sublingual antidepressant and antianxiety lozenge.
  • Ingredient 80 may be in liquid form. Ingredient 80 may be a liquid flavoring.
  • Ingredient 80 may include a liquid confection product. Ingredient 80 may enhance digestion and taste of a sublingual antidepressant and antianxiety lozenge.
  • ingredient 40 may be added to chamber 20 and blended into melted troche base 15.
  • Ingredient 40 may be geometrically diluted into melted troche base 15.
  • Ingredient 40 may be mixed until ingredient 40 is evenly distributed throughout melted troche base 15 as indicated by an even distribution of a color of ingredient 40 throughout melted troche base 15.
  • ingredient 50 may be added to chamber 20 and blended into melted troche base 15.
  • Ingredient 50 may be geometrically diluted into melted troche base 15.
  • Ingredient 50 may be mixed until ingredient 50 is evenly distributed throughout melted troche base 15 as indicated by an even distribution of a color of ingredient 50 throughout melted troche base 15.
  • ingredient 60 may be added to chamber 20 and blended into melted troche base 15.
  • Ingredient 60 may be geometrically diluted into melted troche base 15.
  • Ingredient 60 may be mixed until ingredient 60 is evenly distributed throughout melted troche base 15 as indicated by an even distribution of a color of ingredient 60 throughout melted troche base 15.
  • ingredient 70 may be added to chamber 20 and blended into melted troche base 15.
  • Ingredient 70 may be geometrically diluted into melted troche base 15.
  • Ingredient 70 may be mixed until ingredient 70 is evenly distributed throughout melted troche base 15 as indicated by an even distribution of a color of ingredient 70 throughout melted troche base 15.
  • ingredient 80 may be added to chamber 20 and blended into melted troche base 15.
  • Ingredient 80 may be mixed until ingredient 80 is evenly distributed throughout melted troche base 15 as indicated by an even distribution of a color of ingredient 80 throughout melted troche base 15.
  • a melted lozenge mixture 85 may be formed by mixing ingredients 40, 50,
  • Melted lozenge mixture 85 may be poured into cavities 120 of lozenge mold 90.
  • Lozenge mold 90 may be plastic, anodized aluminum, or some other non-permeable material, and may be configured to form equal sized lozenges.
  • Lozenge mold 90 may include 30 uniformly sized cavities 120.
  • Melted lozenge mixture 85 may be poured into cavities 120 of lozenge mold 90 so as to completely fill cavities 120.
  • a scrapper or spatula 110 may be used to level and even out poured melted lozenge mixture 85 in cavities 120 of lozenge mold 90.
  • Spatula 1 10 may also be used to wipe any excess melted lozenge mixture 85 off of lozenge mold 90.
  • Lozenge mold 90 with cavities 120 filled with melted lozenge mixture 85, may be cooled to room temperature of 20 to 25 degrees Celsius to form lozenge 130.
  • Lozenge 130 may be a solid lozenge with ingredients 40, 50, 60, 70, and 80 distributed evenly throughout lozenge 130. Lozenge 130 may include about 0.35 weight percent to about 0.65 weight percent of ingredient 40. Lozenge 130 may include about 1.05 weight percent to about 1.35 weight percent of ingredient 50. Lozenge 130 may include about 1.20 weight percent to about 1.55 weight percent of ingredient 60. Lozenge 130 may include about 1.80 weight percent to about 2.10 weight percent of ingredient 70.
  • Lozenge 130 may include:
  • Example 2 A mold with 30 uniformly sized cavities may be utilized to mold 30 lozenges 130 from melted lozenge mixture 85 formed from the following quantities:
  • Ingredient 40 may be ketamine HC1 powder.
  • Ingredient 50 may be silica gel powder.
  • Ingredient 60 may be citric acid powder.
  • Ingredient 70 may be acacia powder.
  • Ingredient 80 may be tutti frutti flavor liquid.
  • Lozenge 130 may be formed from the following quantities:
  • lngredient 40 may be ketamine HC1 powder.
  • Ingredient 50 may be silica gel powder.
  • Ingredient 60 may be citric acid powder.
  • Ingredient 70 may be acacia powder.
  • Ingredient 80 may be tutti frutti flavor liquid.
  • Fig. 2 illustrates a flow diagram of an example process to produce a sublingual antidepressant and antianxiety lozenge 130.
  • the process in Fig. 2 could be implemented using, for example, system 100 discussed above.
  • An example process may include one or more operations, actions, or functions as illustrated by one or more of blocks S2, S4, S6, S8, and/or S10. Although illustrated as discrete blocks, various blocks may be divided into additional blocks, combined into fewer blocks, or eliminated, depending on the desired implementation.
  • Processing may begin at block S2, "Place troche base into a chamber.”
  • a troche base may be placed into a chamber.
  • the troche base may be a blend of polyethylene glycols (PEGs).
  • the troche base may be white and/or translucent in appearance and be in the shape of small pellet pieces.
  • the troche base may be solid at room temperatures of 20 to 25 degrees Celsius.
  • Processing may continue from block S2 to block S4, "Apply heat to the chamber sufficient to melt the troche base in the chamber.” At block S4, heat may be applied to the chamber sufficient to melt the troche base. Heat may be applied to the chamber sufficient to increase a temperature of the troche base to about 45 to 60 degrees Celsius and melt the troche base.
  • Processing may continue from block S4 to block S6, "Add a first ingredient into the chamber, wherein the first ingredient includes ketamine.”
  • a first ingredient may be added to the chamber.
  • the first ingredient may include ketamine.
  • the first ingredient may include ketamine hydrochloride (HC1) powder.
  • Processing may continue from block S6 to block S8, "Mix the first ingredient into the melted troche base in the chamber to form a melted mixture.”
  • the first ingredient may be mixed into the melted troche base in the chamber.
  • the mixing may be performed by a manual mixing instrument such as a spoon or whisk, or an automated mixer.
  • the first ingredient may be mixed until the first ingredient is evenly distributed throughout the melted troche base as indicated by an even distribution of a color of the first ingredient throughout the melted troche base.
  • Processing may continue from block S8 to block S10, "Pour the melted mixture into a mold.”
  • the melted mixture may be poured into a mold.
  • the mold may be plastic, anodized aluminum, or some other non-permeable material.
  • the mold may be configured with cavities to form uniform sized lozenges.
  • the melted mixture may be poured into the cavities of the mold.
  • the melted mixture may be poured into the cavities of the mold so as to completely fill the cavities of the mold.
  • a scrapper or spatula may be used to level and even out poured melted mixture in the cavities of the mold.
  • the spatula may also be used to wipe any excess melted mixture off of the mold.
  • Processing may continue from block S10 to block S 12, "Cool the melted mixture in the mold to form the lozenge.”
  • the melted mixture in the mold may be cooled to form the lozenge.
  • the melted mixture may be cooled to room temperature of 20 to 25 degrees Celsius.
  • FIG. 3 illustrates an example system that can be utilized to produce a sublingual antidepressant and antianxiety tablet, arranged in accordance with at least some embodiments presented herein. Those components in Fig. 3 that are labeled identically to components of Fig. 1 -2 will not be described again for the purposes of clarity.
  • System 200 may include chamber 20, mixing instrument 25, a base plate 205, a tablet mold base 210, and a tablet mold top 215.
  • a sublingual tablet base 250 may be placed within chamber 20.
  • Chamber 20 may be an aluminum chamber such as an anodized aluminum chamber.
  • Sublingual tablet base 250 may be a rapid dissolve tablet base and may allow a sublingual antidepressant and antianxiety tablet comprising sublingual tablet base 250 to dissolve sublingually in a time range of 0-60 seconds.
  • mixing instrument 25 may be inserted into chamber 20 and ingredients 40, 230, and 240 may each be individually and respectively added and blended into sublingual tablet base 250.
  • Mixing instrument 25 may be a manual mixing instrument such as a spoon or whisk, or an automated mixer.
  • Ingredient 40 may be in powder form. Ingredient 40 may include ketamine.
  • Ingredient 40 may include ketamine hydrochloride (HC1) powder.
  • Ingredient 230 may be in powder or liquid form.
  • Ingredient 230 may include a flavor lngredient 230 may make a sublingual antidepressant and antianxiety tablet comprising ingredient 230 more palatable.
  • Ingredient 230 may enhance digestion and taste of a sublingual antidepressant and antianxiety tablet comprising ingredient 230.
  • Ingredient 230 may be a raspberry flavor.
  • Ingredient 240 may be in powder or liquid form.
  • Ingredient 240 may be a sweetener.
  • Ingredient 240 may make a sublingual antidepressant and antianxiety tablet comprising ingredient 240 more palatable.
  • Ingredient 240 may enhance digestion and taste of a sublingual antidepressant and antianxiety tablet comprising ingredient 240.
  • Ingredient 240 may include a combination of vanilla and a sugar substitute such as STEVIA.
  • Ingredient 240 may include about 61.5 weight percent vanilla and about 38.5 weight percent STEVIA.
  • ingredient 40 may be added to chamber 20 and blended into sublingual tablet base 250.
  • Ingredient 40 may be geometrically diluted into sublingual tablet base 250.
  • Ingredient 40 may be mixed until ingredient 40 is evenly distributed throughout sublingual tablet base 250 as indicated by an even distribution of a color of ingredient 40 throughout sublingual tablet base 250.
  • ingredient 230 may be added to chamber 20 and blended into sublingual tablet base 250.
  • Ingredient 230 may be geometrically diluted into tablet base 250.
  • Ingredient 230 may be mixed until ingredient 230 is evenly distributed throughout sublingual tablet base 250 as indicated by an even distribution of a color of ingredient 230 throughout sublingual tablet base 250.
  • ingredient 240 may be added to chamber 20 and blended into sublingual tablet base 250.
  • Ingredient 240 may be geometrically diluted into sublingual tablet base 250.
  • Ingredient 240 may be mixed until ingredient 40 is evenly distributed throughout sublingual tablet base 250 as indicated by an even distribution of a color of ingredient 240 throughout sublingual tablet base 250.
  • a tablet mixture 260 may be formed by mixing ingredients 40, 230, and 240 into sublingual tablet base 250.
  • Base plate 205 may be a glass plate or an ointment tile.
  • Tablet mold base 210 may be positioned on top of base plate 205 so that a bottom side of tablet mold base 210 is abutted to base plate 205. Walls of tablet mold base 210 may define openings 220.
  • Tablet mixture 260 may be placed or pressed into openings 220 defined by walls of tablet mold base 210.
  • Tablet mold base 210 may be anodized aluminum, or some other non-permeable material, and may be configured to form uniform sized tablets. Walls of tablet mold base 210 may define 60 uniformly sized openings 220.
  • Tablet mixture 260 may be pressed into openings 220 of tablet mold base 210 so as to completely fill openings 220.
  • spatula 1 10 may be used to press, level, and even out tablet mixture 260 into openings 220 of tablet mold base 210.
  • tablet mold top 215 may be positioned on tablet mold base 210 such that tablet pegs 225 of tablet mold top 215 align with openings 220 defined by walls of tablet mold base 210. Tablet pegs 225 of tablet mold top 215 may press tablet mixture 260 into openings 220 defined by walls of tablet mold base 210.
  • a combination of tablet mold base 210, with openings 220 filled with tablet mixture 260, and tablet mold cover 215, may be heated to dry tablet mixture 260. Drying may be performed by placing the combination of tablet mold base 210 with openings 220 filled with tablet mixture 260 and tablet mold cover 215 by heater 30. Drying may be performed by placing tablet mold base 210 with openings 220 filled with tablet mixture 260 and tablet mold cover 215 in an oven 280. Heater 30 or oven 280 may heat tablet mold base 210 with openings 220 filled with tablet mixture 260 to a temperature of about 90 to 130 degrees Celsius for a time range of 10 to 15 minutes.
  • Drying may be performed by allowing tablet mold base 210 with openings 220 filled with tablet mixture 260 and tablet mold cover 215 to dry at room temperature of 20 to 25 degrees Celsius to form tablet 270. After tablets 270 are dried within tablet mold base 210, pegs 225 of tablet mold top 215 may be used to push tablets 270 out of tablet mold base 210.
  • Tablet 270 may be a solid tablet with ingredients 40, 230, and 240 distributed evenly throughout tablet 270.
  • Tablet 270 may include about 2.00 weight percent to about 23.00 weight percent of ingredient 40.
  • Tablet 270 may include about 0.35 weight percent to about 0.65 weight percent of ingredient 230.
  • Tablet 270 may include about 0.30 weight percent to about 0.50 weight percent of ingredient 240.
  • Tablet 270 may include:
  • a tablet mold base with 60 uniformly sized cavities may be utilized to mold
  • Ingredient 40 may be ketamine HC1 powder
  • Ingredient 230 may raspberry flavor
  • Ingredient 240 may be a combination of vanilla and STEVIA;
  • a tablet mold base with 60 uniformly sized cavities may be utilized to mold
  • Ingredient 40 may be ketamine HC1 powder; [0060] 0.064 grams of ingredient 230. Ingredient 230 may raspberry flavor;
  • Ingredient 240 may be a combination of vanilla and STEVIA;
  • a tablet mold base with 60 uniformly sized cavities may be utilized to mold
  • Ingredient 40 may be ketamine HC1 powder
  • Ingredient 230 may raspberry flavor
  • Ingredient 240 may be a combination of vanilla and STEVIA;
  • Fig. 4 illustrates a flow diagram of an example process to produce a sublingual antidepressant and antianxiety tablet 270.
  • the process in Fig. 4 could be implemented using, for example, system 200 discussed above.
  • An example process may include one or more operations, actions, or functions as illustrated by one or more of blocks S2, S4, S6, S8, and/or S10. Although illustrated as discrete blocks, various blocks may be divided into additional blocks, combined into fewer blocks, or eliminated, depending on the desired implementation.
  • Processing may begin at block S2, "Place sublingual tablet base into a chamber.”
  • a sublingual tablet base may be placed into a chamber.
  • the sublingual tablet base may be a rapid dissolve tablet base and may allow a sublingual antidepressant and antianxiety table comprising the tablet base to dissolve sublingually in a time range of 0-60 seconds.
  • Processing may continue from block S2 to block S4, "Add a first ingredient into the chamber, wherein the first ingredient includes ketamine.”
  • a first ingredient may be added to the chamber.
  • the first ingredient may include ketamine.
  • the first ingredient may include ketamine hydrochloride (HC1) powder.
  • Processing may continue from block S4 to block S6, "Mix the first ingredient into the sublingual tablet base in the chamber to form a mixture.”
  • the first ingredient may be mixed into the sublingual tablet base in the chamber.
  • the mixing may be performed by a manual mixing instrument such as a spoon or whisk, or an automated mixer.
  • the first ingredient may be mixed until the first ingredient is evenly distributed throughout the tablet base as indicated by an even distribution of a color of the first ingredient throughout the tablet base.
  • Processing may continue from block S6 to block S8, "Press the mixture into a mold.”
  • the mixture may be pressed into a mold.
  • the mold may be plastic, anodized aluminum, or some other non-permeable material.
  • the mold may be configured with cavities to form uniform sized tablets.
  • the mixture may be placed or pressed into the cavities of the mold.
  • the mixture may be pressed into the cavities of the mold so as to completely fill the cavities of the mold.
  • a scrapper or spatula may be used to press, level, and even out mixture in the cavities of the mold.
  • a tablet mold top may be positioned on the mold such that tablet dimples of the tablet mold top align with the cavities of the mold base. The tablet dimples of the tablet mold top may press the tablet mixture into the cavities of the mold.
  • Processing may continue from block S8 to block S10, "Dry the mixture in the mold to form the tablet.”
  • the mixture in the mold may be dried to form the tablet.
  • the mold with the cavities filled with the mixture may be heated to dry, such as by a heater, dried in an oven, or allowed to dry at room temperature of 90 to 130 degrees Celsius for a time range of 10 to 15 minutes.
  • a system in accordance with the present disclosure may be effective to produce a sublingual antidepressant and antianxiety lozenge or a sublingual antidepressant and antianxiety tablet.
  • a potential benefit of the present application may be the treatment of depression effects in treatment-resistant depression.
  • An embodiment of the present application may provide a more rapid effect than antidepressant treatments which include therapies that target monoaminergic (MA) systems and require 4-6 weeks of administration to achieve effects.
  • An embodiment of the present application may provide a higher efficacy rate than therapies that target monoaminergic (MA) systems.
  • An embodiment of the present application may provide a treatment for anxiety including anxiety related to post traumatic stress disorder and anxiety related to addiction.
  • An embodiment of the present application may provide a treatment for depression and anxiety including depression and anxiety related to postpartum depression, bipolar disorder, Alzheimer's disease and dementia, and other metal health disorders.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des technologies pour des formulations et des procédés de production de tablettes sublinguales d'antidépresseur et d'anxiolytique. Les tablettes peuvent comprendre une base de tablette sublinguale et de la kétamine. Les tablettes peuvent comprendre de 2.00 % en poids à 23.00 % en poids de kétamine. Les procédés peuvent consister à placer une base de tablette sublinguale dans une chambre. Les procédés peuvent consister à ajouter un premier ingrédient dans la chambre. Le premier ingrédient peut comprendre de la kétamine. Les procédés peuvent consister à mélanger le premier ingrédient dans la base de tablette sublinguale dans la chambre pour former un mélange. Les procédés peuvent consister à presser le mélange dans un moule. Les procédés peuvent consister à sécher le mélange dans le moule pour former la tablette.
PCT/US2019/037698 2018-06-18 2019-06-18 Tablette sublinguale d'antidépresseur et d'anxiolytique Ceased WO2019246074A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/011,085 2018-06-18
US16/011,085 US20180296478A1 (en) 2016-02-12 2018-06-18 Sublingual antidepressant and antianxiety tablet

Publications (1)

Publication Number Publication Date
WO2019246074A1 true WO2019246074A1 (fr) 2019-12-26

Family

ID=68983407

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/037698 Ceased WO2019246074A1 (fr) 2018-06-18 2019-06-18 Tablette sublinguale d'antidépresseur et d'anxiolytique

Country Status (1)

Country Link
WO (1) WO2019246074A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021243399A1 (fr) * 2020-06-02 2021-12-09 Ix Biopharma Limited Procédés de traitement de trouble dépressif majeur et de dépression résistante au traitement

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122198B1 (en) * 1999-11-30 2006-10-17 Panacea Biotec Limited Fast dissolving composition with prolonged sweet taste
US20070059361A1 (en) * 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
WO2010144943A1 (fr) * 2009-05-20 2010-12-23 Ozpharma Pty Ltd Formulations thérapeutiques améliorées
US20140178473A1 (en) * 2009-10-30 2014-06-26 Ix Biopharma Pte Ltd Solid dosage form
US20170231906A1 (en) * 2016-02-12 2017-08-17 Synergistic Therapeutics, Llc Sublingual antidepressant lozenge
WO2018102488A1 (fr) * 2016-11-30 2018-06-07 Wolfson Philip E Kétamine pour le traitement de symptômes liés aux menstruations
US20180296478A1 (en) * 2016-02-12 2018-10-18 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122198B1 (en) * 1999-11-30 2006-10-17 Panacea Biotec Limited Fast dissolving composition with prolonged sweet taste
US20070059361A1 (en) * 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
WO2010144943A1 (fr) * 2009-05-20 2010-12-23 Ozpharma Pty Ltd Formulations thérapeutiques améliorées
US20140178473A1 (en) * 2009-10-30 2014-06-26 Ix Biopharma Pte Ltd Solid dosage form
US20170231906A1 (en) * 2016-02-12 2017-08-17 Synergistic Therapeutics, Llc Sublingual antidepressant lozenge
US20180296478A1 (en) * 2016-02-12 2018-10-18 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
WO2018102488A1 (fr) * 2016-11-30 2018-06-07 Wolfson Philip E Kétamine pour le traitement de symptômes liés aux menstruations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021243399A1 (fr) * 2020-06-02 2021-12-09 Ix Biopharma Limited Procédés de traitement de trouble dépressif majeur et de dépression résistante au traitement

Similar Documents

Publication Publication Date Title
US20180296478A1 (en) Sublingual antidepressant and antianxiety tablet
US10034832B2 (en) Sublingual antidepressant lozenge
RU2395998C2 (ru) Новая карамель и способ ее получения
US20040131751A1 (en) Filled sugar confectionery articles
CN101119641A (zh) 巧克力和巧克力样糖食产品中耐热性的快速形成
JP2022054818A (ja) ゲル化剤組成物、ゲル化性組成物、ゲル化物および立体構造物の製造方法
US11413251B2 (en) Gelatin product comprising a core component and method for producing same
TWI735492B (zh) 澆鑄複合物及用於生產明膠產品之方法
KR101161430B1 (ko) 분자량에 기초하여 선택되는 1 종 이상의 어류 젤라틴을 포함하는 속성 분산형 투약 제형의 제조 방법
WO2019246074A1 (fr) Tablette sublinguale d'antidépresseur et d'anxiolytique
RU2381691C1 (ru) Способ производства ириса с начинкой
US5688521A (en) Lactulose pastilles
JP2009261381A (ja) 冷菓用マシュマロ及びその製造方法
SU1755772A1 (ru) Желейное кондитерское изделие и способ его производства
US20250312295A1 (en) Sublingual substance abuse disorder and anti-addiction lozenge
EP4146008A1 (fr) Composition gommeuse de gélatine et de pectine pour production sans amidon
SU1746997A1 (ru) Способ производства жевательной резинки
LU600832B1 (en) Method of preparing soft candy based on lysine for promoting growth and intellectual development of children and adolescents
RU2103877C1 (ru) Способ производства конфет "ассорти"
RU2530158C1 (ru) Способ приготовления желейных конфет жевательной консистенции
JPS5813352A (ja) キャンデ−の着香法
KR20250167852A (ko) 카라멜 및 그 제조 방법
JPS626636A (ja) カツプ入りの軽焼菓子風プリン及びその製造法
FR3117737A1 (fr) Procédé de préparation de pépites de chocolat contenant des microalgues
RU2253996C1 (ru) Торт "для тебя"

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19823254

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19823254

Country of ref document: EP

Kind code of ref document: A1